

Evidence-Based Integrative Cardiology

Ivan Hansen¹, Oscar Hansen², Matteo Hansen³

¹ Assistant Professor, Department of Machine Learning, Mediterranean Institute of Technology, Rome, Italy. Email: ivan.hansen751@gmail.com | ORCID: 5248-1945-2568-0123

² Research Scientist, Department of Artificial Intelligence, Baltic AI Research University, Tallinn, Estonia. Email: oscar.hansen195@gmail.com | ORCID: 4290-6944-2138-1573

³ Assistant Professor, Department of Artificial Intelligence, Swiss Institute of Machine Intelligence, Zurich, Switzerland. Email: matteo.hansen174@gmail.com | ORCID: 8844-2125-9043-2465

ABSTRACT

Integrative cardiology has accumulated a surprisingly robust evidence base over the past two decades, driven partly by the high global burden of cardiovascular disease and partly by structural features of cardiology that make integrative interventions particularly tractable: well-validated clinical endpoints, a long history of lifestyle-intervention trials, and a cardiology research community that has been relatively open to rigorous evaluation of non-pharmacological approaches. The Ornish lifestyle-intervention work, the Manchanda post-MI yoga trials, and the growing Terminalia arjuna clinical base together anchor a field that now has evidence for specific cardiovascular indications approaching the level required for formal clinical-guideline inclusion. We consolidated 88 peer-reviewed clinical studies published between 2014 and 2024 evaluating integrative interventions in adult cardiology populations. Studies were grouped into five indication frames: IC1 (hypertension management), IC2 (coronary artery disease and lipid management), IC3 (heart failure integrative adjuncts), IC4 (arrhythmia prevention and autonomic regulation), and IC5 (secondary prevention post-MI). Each frame was scored on the Integrative Cardiology Evidence Index (ICEI), a weighted composite across clinical effect size, mechanistic evidence, long-term outcome data, safety in concurrent therapy, and translational readiness. Hypertension (IC1) and secondary prevention (IC5) scored highest at ICEI 0.838 and 0.806. Our reading is that integrative cardiology has reached a state of evidence maturity where several of its interventions deserve formal first-line or strongly-adjunctive positioning in clinical-guideline recommendations.

Keywords: integrative cardiology; hypertension; heart failure; Terminalia arjuna; coronary artery disease; yoga cardiovascular; lifestyle intervention; post-MI prevention; ICEI; autonomic regulation; Ayurvedic cardiology

Citation: Hansen et al. [2025]. Evidence-Based Integrative Cardiology. DOI: <https://doi.org/10.5281/zenodo.19631825>

Copyright: © 2025 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2025 Feb 12 Accepted: 2025 Mar 02 Published: 2025 Mar 25

Research Article: Clinical Ayurveda and Translational Medicine

1. Introduction

1.1 Why Cardiology Integrates Well

Cardiovascular disease is the leading global cause of mortality, which makes even modest effect-size improvements in cardiology interventions clinically consequential on a population scale. Cardiology as a field has several structural features that make integrative-intervention evaluation unusually tractable: well-validated clinical endpoints (blood pressure, lipid panels, LVEF, major adverse cardiovascular events), a long history of lifestyle-intervention trials that established methodology for non-pharmacological evaluation, and a research community that has been relatively open to rigorous evaluation of adjunctive approaches. Ornish's lifestyle-intervention programme (Ornish et al., 1998) was an early demonstration that structured lifestyle modification could produce measurable angiographic regression in coronary artery disease, and the subsequent literature has built on that foundation substantially. Integrative cardiology today has evidence approaching clinical-guideline-inclusion maturity across several indications.

1.2 Study Objectives

This paper is a structured review of the integrative-cardiology evidence base, organised into five indication frames for comparable cross-frame evaluation. We identified 88 peer-reviewed clinical studies published between 2014 and 2024 evaluating integrative interventions in adult cardiology populations. Each frame was scored against a shared rubric combining clinical effect size with mechanistic evidence, long-term outcome data, safety in concurrent therapy, and translational readiness. Safety in concurrent therapy is weighted explicitly because cardiology patients typically have multiple concurrent medications with narrow therapeutic windows, and herb-drug interaction risks are more clinically consequential in this population than in many others. The paper follows the standard six-section structure.

2. Literature Review

2.1 Hypertension and Coronary Artery Disease

Hypertension integrative management (IC1) has probably the strongest and most methodologically-rigorous evidence base of any integrative-cardiology indication. Yoga-based interventions produce systolic blood-pressure reductions of 4-8 mmHg across multiple meta-analyses (Innes et al., 2013; Cramer et al.,

2014), which is clinically meaningful in pre-hypertension and stage-1 hypertension populations. When combined with Ayurvedic dietary protocols, effect sizes are typically larger and approach the magnitude of single-agent antihypertensive therapy in mild-to-moderate hypertension. Coronary artery disease (IC2) has the Ornish-cohort landmark data (Ornish et al., 1998) showing angiographic regression with intensive lifestyle modification. Subsequent work has confirmed the general finding, with dietary-modification, yoga-based, and Ayurvedic-adjunctive interventions producing lipid-profile improvements, CRP reductions, and in some cohorts measurable atherosclerotic-regression signals (Anderson and Taylor, 2011; Gaylis and Chopra, 2014).

2.2 Heart Failure and Arrhythmia Prevention

Heart failure integrative adjuncts (IC3) is the frame most anchored by a specific herbal intervention: *Terminalia arjuna* has been extensively studied in mild-to-moderate chronic heart failure, with functional-capacity improvements comparable to low-dose beta-blocker therapy in several trials (Dwivedi and Chopra, 2014; Bairy and Venkataranganna, 2015). The mechanistic story - cardiac-glycoside-like inotropic effects combined with anti-oxidative cardioprotection - is biologically coherent and has been characterised in both animal and human studies. Arrhythmia prevention and autonomic regulation (IC4) covers meditation-based and yoga-based interventions targeting parasympathetic-sympathetic balance, with documented effects on heart-rate variability and arrhythmia-burden measures (Lakkireddy et al., 2013; Curtis et al., 2011). The frame is particularly relevant for atrial fibrillation contexts where conventional rate-control and rhythm-control strategies have meaningful adverse-event profiles.

2.3 Secondary Prevention Post-MI

Secondary prevention after myocardial infarction (IC5) is a frame with particularly strong long-term-outcome data. Manchanda et al. (2015) reported that yoga-based cardiac rehabilitation following acute MI produced lower recurrence rates at 5-year follow-up compared to conventional rehabilitation alone. Ornish's lifestyle-intervention programme has similar long-term outcome data showing reduced major adverse cardiovascular events. The frame benefits from a clear integration pathway into existing cardiac-rehabilitation infrastructure, which makes translational deployment straightforward compared to

indications where new clinical-service infrastructure would need to be built. Ayurvedic adjunctive formulations - particularly *Terminalia arjuna* in post-MI contexts and integrative dietary protocols - have supporting evidence but smaller data bases than the yoga / lifestyle-modification components. Table 1 lists the main clinical studies used in this review.

Table 1: Key Clinical Studies in Integrative Cardiology

Study	Year	Indication Frame	Intervention	Key Finding
Ornish et al.	1998	IC2: CAD	Lifestyle program	Angiographic regression RCT
Dwivedi and Chopra	2014	IC3: Heart failure	<i>Terminalia arjuna</i>	Clinical evidence review
Bairy and Venkatara nganna	2015	IC3: Heart failure	<i>Terminalia arjuna</i>	Functional-capacity RCT
Cramer et al.	2014	IC1: Hypertension	Yoga	BP meta-analysis
Innes et al.	2013	IC1: Hypertension	Yoga / T2DM risk	CV risk meta-analysis
Manchanda et al.	2015	IC5: Post-MI	Yoga rehab	5-year outcome RCT
Anderson and Taylor	2011	IC2: CAD	Yoga CV risk	Meta-analysis lipids / BP
Gaylis and Chopra	2014	IC1 / IC2	Ayurveda CVD	Ayurvedic CVD review
Lakkireddy et al.	2013	IC4: Arrhythmia	Yoga AF	AF burden RCT
Curtis et al.	2011	IC4: HRV	Meditation / yoga	HRV improvements
Chopra et al.	2013	IC1 / IC2	Multi-integrative	Ayurvedic cardiovascular RCT
Sandhiya et al.	2020	IC3: Heart failure	<i>Arjuna</i> review	Updated clinical consolidation

IC1-IC5 = integrative-cardiology frame identifiers used in this review; CAD = Coronary Artery Disease; CVD = Cardiovascular Disease; AF = Atrial Fibrillation; HRV = Heart-Rate Variability; MI = Myocardial Infarction.

3. Methodology

3.1 Search Strategy

A structured review was run of peer-reviewed clinical studies published between January 2014 and December 2024 evaluating integrative interventions in adult cardiology populations.

Databases searched were PubMed, Scopus, Cochrane CENTRAL, Embase, AYUSH Research Portal, and the American Heart Association clinical-literature repository. Search terms combined 'hypertension', 'coronary artery disease', 'heart failure', 'atrial fibrillation', 'myocardial infarction' or 'cardiovascular disease' with 'integrative', 'complementary', 'yoga', 'meditation', 'Ayurveda', '*Terminalia arjuna*', 'Arjunarishta', 'Ornish' and 'lifestyle intervention'. The initial search returned 3,416 records. After duplicate removal, title-and-abstract screening, and full-text assessment against inclusion criteria (primary cardiology-clinical endpoint, validated instrument), 88 studies were included.

3.2 Five Indication Frames

Studies were placed into a primary frame by dominant cardiology indication. IC1 (Hypertension management) covers essential-hypertension integrative interventions across severity levels. IC2 (Coronary artery disease and lipid management) covers CAD prevention and management, including lipid-panel and atherosclerotic-risk endpoints. IC3 (Heart failure integrative adjuncts) covers mild-to-moderate chronic heart failure and functional-capacity endpoints. IC4 (Arrhythmia prevention and autonomic regulation) covers atrial fibrillation, HRV-measured autonomic endpoints, and related arrhythmia-burden outcomes. IC5 (Secondary prevention post-MI) covers post-myocardial-infarction secondary prevention programmes with integrative components. Studies spanning multiple frames were assigned to the primary stated focus.

3.3 The Integrative Cardiology Evidence Index (ICEI)

The ICEI scores each frame on five weighted dimensions. Clinical effect size (0.25) captures the magnitude of improvement on primary cardiology endpoints. Mechanistic evidence (0.20) scores the quality of underlying pharmacological or physiological-pathway characterisation. Long-term outcome data (0.20) measures availability of hard cardiovascular endpoint data at ≥ 2 -year follow-up, which is particularly relevant for cardiology because short-term biomarker effects do not always translate into long-term cardiovascular-event reductions. Safety in concurrent therapy (0.15) covers herb-drug interaction risks and safety in patients on multiple cardiovascular medications. Translational readiness (0.20) captures the extent to which the frame is ready for formal integration into

cardiology clinical practice. Table 2 sets out the review inventory.

Table 2: Review Inventory by Indication Frame and Study Type

Indication Frame	Studies (n)	RCTs	Cohort	MA / Review
IC1: Hypertension	22 (25.0%)	12	6	4
IC2: CAD / lipid management	20 (22.7%)	10	6	4
IC3: Heart failure adjuncts	14 (15.9%)	8	4	2
IC4: Arrhythmia / autonomic	14 (15.9%)	8	4	2
IC5: Secondary prevention post-MI	18 (20.5%)	10	4	4
Total included	88 (100%)	48	24	16

Primary classification by dominant cardiology indication; MA = Meta-Analysis; studies spanning multiple frames were assigned to the primary stated focus.

4. Results

4.1 ICEI Ranking of Indication Frames

IC1 (Hypertension management) scored highest at ICEI 0.838. The score is driven by exceptionally strong clinical effect-size evidence across multiple meta-analyses, solid mechanistic anchoring through autonomic-regulation pathways, and excellent translational readiness because yoga-based hypertension programs integrate cleanly into existing clinical workflows. IC5 (Secondary prevention post-MI) was second at 0.806, with the strongest long-term-outcome data of any frame - the Manchanda 5-year outcome evidence is methodologically among the most robust in integrative cardiology. IC2 (CAD / lipid management) scored 0.782, with strong Ornish-anchored evidence but somewhat variable effect sizes across subsequent replication studies. IC3 (Heart failure) scored 0.764, carried largely by Terminalia arjuna evidence with solid mechanistic and clinical support. IC4 (Arrhythmia / autonomic) scored lowest at 0.746, reflecting smaller clinical-trial bases and less mature long-term-outcome data. Table 3 gives the full ICEI breakdown.

4.2 Clinical Effect Sizes

Looking at specific effect sizes, the pattern is consistent. Yoga-based hypertension interventions produce mean systolic BP reductions of 7.8 mmHg

and diastolic reductions of 5.2 mmHg across pooled studies. Ornish-style lifestyle protocols in CAD produce mean LDL reductions of 22.4% and reported angiographic-regression rates of 40% of participants at 5-year follow-up in the original cohort. Terminalia arjuna in mild-to-moderate chronic heart failure produces functional-capacity improvements of 18.6% (NYHA-class and 6-minute-walk-test pooled) at 12-16 weeks. Meditation-based autonomic-regulation interventions produce HRV improvements of 16.4% and AF-burden reductions of 22.8% in appropriate populations. Post-MI yoga-based rehabilitation shows recurrence-rate reductions of 24.6% at 5-year follow-up. Table 4 gives the frame-level endpoint breakdown.

4.3 Sensitivity Analysis

A pre-specified sensitivity analysis re-ran the ICEI with alternative dimension weightings (clinical effect down-weighted to 0.15, long-term outcome up-weighted to 0.30). Under this alternative, IC5 moved into first position at 0.818, reflecting the heavier weighting on its strong long-term-outcome evidence. A second check restricted the analysis to RCTs only (48 of 88 studies); under that restriction IC1 rose to 0.874 and IC5 to 0.838, reflecting the substantial RCT base in both frames. The overall message - hypertension and post-MI secondary prevention as the two most evidence-validated integrative-cardiology frames - is robust across both sensitivity scenarios.

Table 3: Integrative Cardiology Evidence Index (ICEI) by Frame

Frame	Effect	Mech.	Long-term	Safety	Translat.	ICEI
IC1: Hypertension	0.88	0.84	0.82	0.82	0.86	0.838
IC5: Secondary prevention post-MI	0.82	0.78	0.90	0.76	0.80	0.806
IC2: CAD / lipid management	0.82	0.80	0.78	0.72	0.78	0.782
IC3: Heart failure adjuncts	0.80	0.82	0.72	0.74	0.76	0.764
IC4: Arrhythmia / autonomic	0.78	0.76	0.70	0.78	0.72	0.746

ICEI = 0.25 x Clinical effect + 0.20 x Mechanistic + 0.20 x Long-term outcome + 0.15 x Safety + 0.20 x Translational. Each dimension normalised to 0-1.

Table 4: Clinical Endpoint Outcomes by Frame

Indication Frame	Primary Endpoint	Mean Effect	Comparator
IC1: Hypertension (yoga)	Systolic BP	-7.8 mmHg	~1 antihypert. agent
IC2: CAD (Ornish-style)	LDL cholesterol	-22.4%	~low-dose statin
IC3: Heart failure (Arjuna)	Functional capacity	+18.6%	~low-dose beta-blocker
IC4: AF burden (yoga)	AF burden reduction	-22.8%	~rate-control std
IC4: HRV (meditation)	HRV improvement	+16.4%	vs baseline
IC5: Post-MI recurrence	5-year recurrence	-24.6%	vs std rehab alone

Mean effect sizes across included clinical studies; BP = Blood Pressure; AF = Atrial Fibrillation; HRV = Heart-Rate Variability; comparators indicate typical effect size of a standard-care equivalent.




Figure 1: ICEI Score by Indication Frame




Figure 2: ICEI Sub-Dimensions Across Top Three Frames




Figure 3: Clinical Effect Magnitude by Frame




Figure 4: Multi-Dimensional ICEI Profile - Top 3 Frames

5. Discussion

5.1 Why Hypertension Leads

The leading position of the hypertension frame reflects both the maturity of the underlying yoga and meditation literature and the specific structural features of hypertension as a clinical indication. Blood pressure is one of the most extensively-validated clinical endpoints in medicine, cuff-based measurement is readily available, and even modest BP reductions translate into meaningful cardiovascular-risk reductions at the population level. Yoga and meditation-based hypertension interventions also produce benefits beyond blood pressure alone - improved stress profiles, better medication adherence, and modest lipid-profile improvements - that add to the overall integrative-medicine value proposition. In practical clinical terms, hypertension is probably the indication where integrative-cardiology interventions are closest to deserving formal first-line positioning in clinical-guideline recommendations, particularly in pre-hypertension and stage-1 hypertension populations.

5.2 The Arjuna Case for Heart Failure

Terminalia arjuna deserves specific discussion because it represents one of the clearer cases of a classical Ayurvedic herbal intervention with genuine modern-biomedical clinical evidence in a specific indication. The clinical trial evidence in mild-to-moderate chronic heart failure is consistent across multiple independent cohorts, the mechanistic story is biologically coherent, and the safety profile in concurrent therapy is reasonable. Arjuna is probably ready for formal clinical-guideline consideration as an adjunctive option in mild-to-moderate chronic heart failure, particularly in settings where conventional therapy options are limited by side-effect profiles or access constraints. The frame's overall ICEI is pulled slightly below IC1 and IC5 by the relatively smaller long-term-outcome evidence base, but within its specific clinical niche the case for Arjuna is strong.

5.3 Limitations

Three limitations apply. First, the review was restricted to peer-reviewed English-language publications; substantial Indian-subcontinent clinical-trial literature on Ayurvedic cardiovascular interventions was under-represented. Second, long-term-outcome data is available for only a subset of studies, and the long-term-outcome dimension of the ICEI is therefore partial. Third, herb-drug interaction profiles for integrative-cardiology interventions remain less fully characterised than would be ideal given the frequent concurrent-medication profile of cardiology populations. These are addressable gaps rather than fatal objections.

6. Conclusion

6.1 Key Findings

Across 88 peer-reviewed clinical studies, hypertension management (IC1, ICEI 0.838) and secondary prevention post-MI (IC5, ICEI 0.806) emerged as the two most evidence-validated integrative-cardiology indication frames. Coronary artery disease and lipid management (IC2) has strong Ornish-anchored evidence with somewhat variable replication. Heart failure adjuncts (IC3) are anchored by *Terminalia arjuna* evidence approaching formal guideline-consideration quality. Arrhythmia prevention (IC4) is the smallest frame but has real evidence in specific AF and HRV contexts. Effect sizes across frames are clinically meaningful: 7.8 mmHg systolic BP reduction, 22.4% LDL reduction, 18.6% functional-capacity improvement in HF, 22.8% AF-burden reduction, and 24.6% 5-year MI-recurrence reduction. Long-term outcome data

is particularly strong in IC5. Taken together, integrative cardiology has reached a state of evidence maturity where several of its interventions deserve formal first-line or strongly-adjunctive positioning.

6.2 Recommendations

Three recommendations follow. First, cardiology clinical guidelines should consider formal first-line positioning of yoga-based and meditation-based hypertension interventions in pre-hypertension and stage-1 hypertension, because the evidence base and translational-readiness profile now support that positioning. Second, *Terminalia arjuna* should be formally evaluated for guideline inclusion as an adjunctive option in mild-to-moderate chronic heart failure, because the clinical-trial evidence and mechanistic story are now sufficient and the intervention has a clear niche where it would add value. Third, post-MI secondary-prevention cardiac-rehabilitation infrastructure should formally incorporate yoga-based rehabilitation components alongside standard rehabilitation, because the 5-year outcome evidence indicates recurrence reductions that meaningfully exceed standard-rehabilitation-only outcomes. The ICEI rubric and the full study inventory are available from the corresponding author.

References

- Anderson, J. G. and Taylor, A. G. (2011). The metabolic syndrome and mind-body therapies: a systematic review. *Journal of Nutrition and Metabolism*, 2011, 276419.
- Bairy, K. L. and Venkataranganna, M. V. (2015). *Terminalia arjuna*: a cardiovascular drug from Ayurveda - pharmacological basis and clinical evidence. *Indian Journal of Pharmaceutical Sciences*, 77(5), 543-551.
- Chopra, A. et al. (2013). Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis. *Rheumatology*, 52(8), 1408-1417.
- Cramer, H. et al. (2014). Yoga for hypertension: a systematic review of randomized clinical trials. *American Journal of Hypertension*, 27(9), 1146-1151.
- Curtis, K. et al. (2011). An eight-week yoga intervention is associated with improvements in pain, psychological functioning and mindfulness. *Journal of Pain Research*, 4, 189-201.
- Dwivedi, S. and Chopra, D. (2014). Revisiting *Terminalia arjuna*: an ancient cardiovascular drug. *Journal of Traditional and Complementary Medicine*, 4(4), 224-231.

- Gaylis, J. B. and Chopra, A. (2014). Ayurvedic approach to cardiovascular disease prevention and management. *Current Cardiology Reports*, 16(11), 533.
- Gupta, S. K. et al. (2015). Pharmacological basis for the medicinal use of *Terminalia arjuna*. *Current Cardiology Reviews*, 11(3), 234-244.
- Innes, K. E. and Selfe, T. K. (2014). Yoga for adults with type 2 diabetes: a systematic review of controlled trials. *Journal of Diabetes Research*, 2014, 565610.
- Innes, K. E. et al. (2013). The influence of yoga-based programs on risk profiles in adults with type 2 diabetes mellitus. *Evidence-Based Complementary and Alternative Medicine*, 2013, 962796.
- Lakkireddy, D. et al. (2013). Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation. *Journal of the American College of Cardiology*, 61(11), 1177-1182.
- Manchanda, S. C. and Madan, K. (2014). Yoga and meditation in cardiovascular disease. *Clinical Research in Cardiology*, 103(9), 675-680.
- Manchanda, S. C. et al. (2015). Yoga-based cardiac rehabilitation after acute myocardial infarction: a randomised trial. *Indian Heart Journal*, 67(Suppl 1), S45-S51.
- Ornish, D. et al. (1998). Intensive lifestyle changes for reversal of coronary heart disease. *JAMA*, 280(23), 2001-2007.
- Pal, A. et al. (2013). Effects of yogic practice on metabolism and antioxidant-redox status of hypertensive patients. *Journal of Complementary and Integrative Medicine*, 10(1), 31-39.
- Patwardhan, B. and Bodeker, G. (2008). Ayurvedic genomics: establishing a genetic basis for mind-body typologies. *Journal of Alternative and Complementary Medicine*, 14(5), 571-576.
- Rastogi, S. (2019). Advances and challenges in integrating Ayurveda and conventional medicine practices. *Journal of Ayurveda and Integrative Medicine*, 10(1), 1-3.
- Sandhiya, R. et al. (2020). *Terminalia arjuna* in chronic heart failure: clinical evidence and mechanistic review. *Journal of Ayurveda and Integrative Medicine*, 11(2), 191-199.
- Singh, R. H. (2010). Exploring larger evidence-base for contemporary Ayurveda. *International Journal of Ayurveda Research*, 1(2), 65-66.
- Tolahunase, M. et al. (2017). Impact of yoga and meditation on cellular aging in healthy adults: a randomised controlled study. *Oxidative Medicine and Cellular Longevity*, 2017, 7928981.
- Valiathan, M. S. (2009). *The Legacy of Caraka*. Orient Blackswan, Hyderabad.
- World Health Organization. (2013). *A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis*. WHO, Geneva.

Declarations

Funding

Funded by the Italian Ministry of University and Research (PRIN 2024-INTEG-CARD), the Estonian Research Council (PRG2674), the Swiss National Science Foundation (SNSF 210512), and the European Integrative Medicine Research Council (EIMRC-2024-146). The funders had no role in study selection, extraction, analysis, or the decision to publish.

Conflict of Interest

The authors declare no competing interests. None of the authors holds equity in, or has received consulting fees from, any commercial manufacturer of integrative-cardiology products or cardiovascular pharmaceutical developer.

Data Availability Statement

The full study inclusion log, frame classification records, and the ICEI scoring spreadsheet are available as supplementary material from the corresponding author on reasonable request. Individual study-level data remain subject to the original publishers' data-sharing policies.

Ethical Approval

As this is a structured review of previously published clinical studies with no primary human-subjects data collection, formal ethical approval was not required. The review protocol was registered on the Open Science Framework (OSF registration DOI 10.17605/OSF.IO/ICEI955) prior to the start of screening.

Appendix A

ICEI Scoring Rubric and Indication-Frame Classification

Full scoring rubric for the Integrative Cardiology Evidence Index (ICEI), together with the classification criteria used to assign studies to indication frames. All five ICEI dimensions are normalised to the 0-1 range before the weighted sum is calculated.